Geode Capital Management LLC Has $501,000 Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Geode Capital Management LLC raised its stake in Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 49.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 79,716 shares of the company’s stock after buying an additional 26,489 shares during the quarter. Geode Capital Management LLC owned 0.41% of Nuvectis Pharma worth $501,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Nuvectis Pharma in the 2nd quarter valued at $58,000. Nations Financial Group Inc. IA ADV bought a new stake in shares of Nuvectis Pharma in the third quarter worth about $63,000. GSA Capital Partners LLP raised its position in shares of Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after purchasing an additional 1,790 shares during the period. Iridian Asset Management LLC CT acquired a new stake in shares of Nuvectis Pharma during the third quarter worth about $348,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Nuvectis Pharma by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after purchasing an additional 12,800 shares in the last quarter. Institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Stock Performance

NASDAQ NVCT opened at $5.81 on Friday. The stock has a market cap of $112.26 million, a price-to-earnings ratio of -5.01 and a beta of 0.17. The business has a 50 day simple moving average of $5.79 and a 200 day simple moving average of $6.38. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter last year, the firm posted ($0.37) earnings per share. On average, analysts predict that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were purchased at an average price of $4.70 per share, for a total transaction of $79,900.00. Following the purchase, the insider now owns 2,612,000 shares of the company’s stock, valued at approximately $12,276,400. The trade was a 0.66 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ron Bentsur purchased 20,000 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were acquired at an average cost of $4.92 per share, with a total value of $98,400.00. Following the completion of the purchase, the chief executive officer now directly owns 3,266,424 shares in the company, valued at approximately $16,070,806.08. This represents a 0.62 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 43,500 shares of company stock valued at $209,205. Company insiders own 35.78% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.